BioStock: Respiratorius marches towards partnering deal

Things are heating up for the development company Respiratorius and its drug candidate VAL001. Step by step, a potential partnering deal is getting closer and expectations are in the air. These expectations can also be felt when the company publishes its Q2 report for the fiscal year 2022/2023. BioStock contacted CEO Johan Drott to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/11/respiratorius-marches-towards-partnering-deal/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se